⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer

Official Title: Are the Proteomic Profiles of Serum and Urine Predictivefor Clinical Outcome After Definitive Radiotherapy for Localized Prostate Cancer? A Preliminary Cohort Study

Study ID: NCT00045331

Conditions

Prostate Cancer

Interventions

proteomic profiling

Study Description

Brief Summary: RATIONALE: Proteins found in blood and urine samples may help predict outcome and allow doctors to plan more effective treatment. PURPOSE: Diagnostic trial to study blood and urine proteins in predicting treatment outcome in patients who are undergoing radiation therapy for prostate cancer.

Detailed Description: OBJECTIVES: * Correlate serum and urine protein profiles collected before or after radiotherapy with clinical outcome in patients with prostate cancer. * Identify protein profiles that can distinguish between patients with no evidence of disease and those with biochemical and/or clinical failure. * Determine whether those serum proteomic profiles consistent with failure can be identified at early time points in the course of treatment and follow-up of these patients. OUTLINE: Patients are stratified according to clinical outcome (prior to radiotherapy vs no evidence of disease vs biochemical failure vs clinical failure vs clinical outcome not yet determined). Urine and blood specimens are collected from patients either before or after definitive radiotherapy. Samples are analyzed by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry to develop proteomic patterns. Results of proteomic profiles do not influence patient care. PROJECTED ACCRUAL: A total of 150 patients (30 per stratum) will be accrued for this study.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

NCI - Center for Cancer Research, Bethesda, Maryland, United States

Contact Details

Name: Kevin Camphausen, MD

Affiliation: NCI - Radiation Oncology Branch; ROB

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: